Investor Presentaiton

Novo Nordisk Annual Report 2023 Balance sheet at 31 December Introducing Novo Nordisk Strategic Aspirations Risks Management Consolidated statements Additional information. 52 52 DKK million Assets Intangible assets Note 2023 2022 DKK million Note 2023 2022 Equity and liabilities 3.1 60,406 50,939 Share capital 4.3 451 456 Property, plant and equipment 3.2 90,961 66,671 Treasury shares 4.3 (5) (6) Investments in associated companies 410 327 Retained earnings 104,839 80,587 Deferred income tax assets 2.6 20,380 13,904 Other reserves 4.3 1,276 2,449 Other receivables and prepayments 1,430 206 Total equity 106,561 83,486 Other financial assets Total non-current assets 1,253 174,840 1,016 Borrowings 4.6 20,528 24,318 133,063 Deferred income tax liabilities 2.6 10,162 7,061 Inventories Trade receivables 3.3 31,811 24,388 Retirement benefit obligations 742 762 3.4 64,770 50,560 Other liabilities 189 100 Tax receivables 2,423 940 Provisions 3.5 6,649 4,590 Other receivables and prepayments 8,068 6,005 Total non-current liabilities 38,270 36,831 Marketable securities 4.4 15,838 10,921 Borrowings 4.6 6,478 1,466 Derivative financial instruments 4.5 2,344 2,727 Trade payables 25,606 15,587 Cash at bank Total current assets Total assets 4.7 14,392 139,646 12,653 108,194 Tax payables 7,116 7,091 Other liabilities 28,705 23,606 314,486 241,257 Derivative financial instruments 4.5 1,272 2,903 Provisions 3.5 100,478 70,287 Total current liabilities 169,655 120,940 Total liabilities 207,925 157,771 Total equity and liabilities 314,486 241,257

View entire presentation